All AbMole products are for research use only, cannot be used for human consumption.
Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively.
Front Cell Neurosci. 2021 Oct 1;15:735723.
The Expression and Roles of the Super Elongation Complex in Mouse Cochlear Lgr5+ Progenitor Cells
Flavopiridol purchased from AbMole
 |
Source | Front Cell Neurosci. 2021 Oct. Figure 4. flavopiridol (Abmole Bioscience, USA) |
| Method | mice treatment | |
| Cell Lines | Lgr5+ cells | |
| Concentrations | 10 μM | |
| Incubation Time | 5 days | |
| Results | The flavopiridol treatment decreased both the number (Figure 4c) and diameter of the spheres (Figure 4d), which suggested that inhibition of the SEC could decrease the sphere-forming ability and proliferation ability of Lgr5+ progenitors in vitro. |
| Cell Experiment | |
|---|---|
| Cell lines | ovarian tumor cell line A2780/ DDP-S |
| Preparation method | 72 h Proliferation Assay. In vitro cytotoxicity was assessed in tissue culture cells by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tetrazolium, inner salt) assay as previously described.23 Depending upon the cell line used, cells were plated at a density of 3000- 6000 cells/well, in a 96 well plate, and 24 h later, drugs were added and serial-diluted. The cells were incubated at 37 °C for 72 h at which time the tetrazolium dye, MTS in combination with phenazine methosulfate, was added. After 3 h, the absorbency was measured at 492 nm, which is proportional to the number of viable cells. The results are expressed as IC50 values. |
| Concentrations | 0~10 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | A2780 human ovarian carcinoma xenograft model in nude mice |
| Formulation | dissolved in a mixture of Cremophor/ ethanol (50:50) , final dilution to the required dosage strength was made with water |
| Dosages | 7.5mg/kg qdx8 |
| Administration | i.p. |
| Molecular Weight | 401.84 |
| Formula | C21H20ClNO5 |
| CAS Number | 146426-40-6 |
| Solubility (25°C) | DMSO 15 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related CDK Products |
|---|
| AT7519
AT7519 is a novel small molecule multi-cyclin-dependent (CDK) kinase inhibitor. |
| R547
R547 is a potent and selective ATP-competitive CDK inhibitor, with Ki values of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively. |
| JNJ-7706621
JNJ-7706621 is a dual cell cycle inhibitor with activity against cyclin-dependent kinases (CDK1, 2, 3, 6) with an IC50 of 3-175 nM and Aurora kinases (A and B) with an IC50 of 11-15 nM respectively. |
| PD 0332991 HCL
PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| SCH727965 (dinaciclib)
SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
